FIELD: organic chemistry, medicine, oncology, pharmacy.
SUBSTANCE: invention relates to quinazoline derivatives of the formula (I) 
or their pharmaceutically acceptable salts wherein m = 0 or 1; each group R1 can be similar or different and represents halogen atom, hydroxy- and (C1-C6)-alkoxy-group, or group of the formula Q3-X1 wherein X1 represents oxygen atom (O); Q3 represents phenyl-(C1-C6)-alkyl, heteroaryl-(C1-C6)-alkyl, heterocyclyl or heterocyclyl-(C1-C6)-alkyl, and wherein heteroaryl group represents aromatic 5- or 6-membered monocyclic rings with one or two nitrogen heteroatoms, and any heterocyclyl group defined as the group R1 represents non-aromatic saturated or partially saturated 3-6-membered monocyclic ring with one or two heteroatoms chosen from oxygen and nitrogen atoms, and wherein adjacent carbon atoms in any (C2-C6)-alkylene chain in the substitute R1 are separated optionally by incorporation of oxygen atom (O) in the chain, and wherein any group CH2 or CH3 in the substitute R1 comprises optionally in each of indicated groups CH2 or CH3 one or some halogen substitutes or a substitute chosen from hydroxy-, (C1-C6)-alkoxy-group, (C1-C6)-alkylsulfonyl or pyridyloxy-group, and wherein any heteroaryl or heterocyclyl group in the substitute R1 comprises optionally 1, 2 or 3 substitutes that can be similar or different and chosen from hydroxy-group, carbamoyl, (C1-C6)-alkyl, (C1-C6)-alkoxycarbonyl, N-(C1-C6)-alkylcarbamoyl, N,N-di-[(C1-C6)-alkyl]-carbamoyl, (C1-C6)-alkoxy-(C1-C6)-alkyl and cyano-(C1-C6)-alkyl, or among group of the formula -X5-Q6 wherein X5 represents a direct bond or -CO, and Q6 represents heterocyclyl or heterocyclyl-(C1-C6)-alkyl that comprises optionally (C1-C6)-alkyl as a substitute wherein heterocyclyl group represents non-aromatic, fully or partially saturated 5- or 6-membered monocyclic ring with one or two heteroatoms chosen from nitrogen and oxygen atom; R2 represents hydrogen atom; R3 represents hydrogen atom; Z represents a direct bond or oxygen atom; Q1 represents phenyl, (C3-C7)-cycloalkyl, heteroaryl-(C1-C6)-alkyl, heterocyclyl or heterocyclyl-(C1-C6)-alkyl wherein heteroaryl group represents 5- or 6-membered aromatic monocyclic ring with I, 2 or 3 heteroatoms of nitrogen, and any heterocyclyl group represents non-aromatic fully or partially saturated 5- or 6-membered monocyclic ring with one or two heteroatoms chosen from oxygen, nitrogen or sulfur atom, or when Z represents oxygen atom (O) then Q1 can represent (C1-C6)-alkyl or (C1-C6)-alkoxy-(C1-C6)-alkyl and wherein any heterocyclyl group in the group -Q1-Z- comprises substitutes chosen from (C1-C6)-alkyl, (C1-C)-alkoxycarbonyl and pyridylmethyl, and wherein any heterocyclyl group in the group -Q1-Z- comprises optionally 1 or 2 oxo-substitutes; Q2 represents aryl group of the formula (Ia): 
wherein G1 represents halogen atom, trifluoromethyl, (C1-C6)-alkyl, (C2-C8)-alkenyl, (C2-C8)-alkynyl, (C1-C6)-alkoxy-, (C1-C6)-alkylthio-group, (C2-C6)-alkanoyl, pyrrolyl, pyrrolidinyl, piperidinyl and morpholinomethyl, and each G2, G3, G4 and G5 that can be similar or different represents hydrogen, halogen atom, cyano-group, (C1-C6)-alkyl, (C2-C8)-alkenyl, (C2-C8)-alkynyl and (C1-C6)-alkoxy-group, or G1 and G2 form in common group of formulae -CH=CH-CH=CH-, -CH=CH-O- or -O-CH=CH- being each group carries optionally halogen atom as a substitute, or G1 and G2 form in common group of formulae -O-CH2-O- or -O-CH2-CH2-O-, or -O-CH2-CH2-O-, and each among G3 and G4 represents hydrogen atom, and G5 is chosen from hydrogen and halogen atom. Proposed compounds possess anti-tumor activity and designated for preparing a medicine preparation for its using as an anti-tumor agent for suppression and/or treatment of solid tumors. Also, invention relates to a pharmaceutical composition based on abovementioned compounds.
EFFECT: valuable medicinal properties of compounds.
20 cl, 7 tbl, 57 ex
| Title | Year | Author | Number |
|---|---|---|---|
| QUINAZOLINE DERIVATIVES, METHOD FOR THEIR PREPARING AND PHARMACEUTICAL COMPOSITION | 2001 |
|
RU2267489C2 |
| AMIDE DERIVATIVES, METHOD FOR PRODUCTION THEREOF (VARIANTS), PHARMACEUTICAL COMPOSITION AND INHIBITION METHOD | 2000 |
|
RU2260007C2 |
| DERIVATIVES OF AMIDE, METHODS FOR THEIR PREPARING, PHARMACEUTICAL COMPOSITION, METHOD OF TREATMENT | 2000 |
|
RU2284187C2 |
| DERIVATIVES OF QUINAZOLINE AS INHIBITORS OF ANGIOGENESIS | 2000 |
|
RU2262935C2 |
| DERIVATIVES OF QUINAZOLINE, METHODS OF THEIR SYNTHESIS, PHARMACEUTICAL COMPOSITIONS COMPRISING THEREOF, METHOD OF ATTAINMENT OF ANTIANGIOGENIC EFFECT AND/OR EFFECT OF BLOOD VESSEL PERMEABILITY REDUCTION IN WARM-BLOODED ANIMAL | 1997 |
|
RU2198879C2 |
| PYRROLIDINE AND PIPERIDINE COMPOUNDS | 2020 |
|
RU2803455C1 |
| DERIVATIVES OF BENZAMIDE, METHOD FOR THEIR PREPARING AND PHARMACEUTICAL COMPOSITION BASED ON THEREOF | 1999 |
|
RU2215736C2 |
| 8-METHYL-1-PHENYLIMIDAZO[1,5-a]PYRAZINE COMPOUNDS | 2011 |
|
RU2560162C2 |
| 1,2,4-TRIAZOLE DERIVATIVES AS SIGMA RECEPTOR INHBITORS | 2007 |
|
RU2451015C2 |
| AMIDE DERIVATIVES | 2004 |
|
RU2375352C2 |
